ATE180772T1 - Durch peptidylketon aktivierte inhibitoren, die natürliche und nicht-natürliche peptidsequenzen enthalten - Google Patents
Durch peptidylketon aktivierte inhibitoren, die natürliche und nicht-natürliche peptidsequenzen enthaltenInfo
- Publication number
- ATE180772T1 ATE180772T1 AT93920167T AT93920167T ATE180772T1 AT E180772 T1 ATE180772 T1 AT E180772T1 AT 93920167 T AT93920167 T AT 93920167T AT 93920167 T AT93920167 T AT 93920167T AT E180772 T1 ATE180772 T1 AT E180772T1
- Authority
- AT
- Austria
- Prior art keywords
- amino acid
- group
- alpha
- natural
- substituted
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000002576 ketones Chemical class 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 4
- 150000001370 alpha-amino acid derivatives Chemical group 0.000 abstract 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 2
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 abstract 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 2
- 235000008206 alpha-amino acids Nutrition 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 abstract 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 abstract 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229960003104 ornithine Drugs 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- -1 phenoxy, substituted phenoxy Chemical group 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/932,791 US5374623A (en) | 1992-08-20 | 1992-08-20 | Cysteine protease inhibitors effective for in vivo use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE180772T1 true ATE180772T1 (de) | 1999-06-15 |
Family
ID=25462930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93920167T ATE180772T1 (de) | 1992-08-20 | 1993-08-18 | Durch peptidylketon aktivierte inhibitoren, die natürliche und nicht-natürliche peptidsequenzen enthalten |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5374623A (de) |
| EP (1) | EP0667854B1 (de) |
| JP (1) | JPH08502245A (de) |
| AT (1) | ATE180772T1 (de) |
| AU (1) | AU5019093A (de) |
| CA (1) | CA2142839A1 (de) |
| DE (1) | DE69325178T2 (de) |
| WO (1) | WO1994004172A1 (de) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874424A (en) * | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US6204261B1 (en) * | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| US6008217A (en) * | 1995-12-20 | 1999-12-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US5985838A (en) * | 1993-04-29 | 1999-11-16 | Vertex Pharmaceuticals, Inc. | Peptide analogs as irreversible interleukin-1β protease inhibitors |
| US5714484A (en) * | 1993-12-08 | 1998-02-03 | Prototek, Inc. | α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors |
| AU1596895A (en) * | 1994-01-25 | 1995-08-08 | G.D. Searle & Co. | Malarial aspartic protease inhibitors |
| IL112759A0 (en) | 1994-02-25 | 1995-05-26 | Khepri Pharmaceuticals Inc | Novel cysteine protease inhibitors |
| US5501969A (en) | 1994-03-08 | 1996-03-26 | Human Genome Sciences, Inc. | Human osteoclast-derived cathepsin |
| US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5847135A (en) * | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US6420522B1 (en) | 1995-06-05 | 2002-07-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US5756466A (en) * | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5498616A (en) * | 1994-11-04 | 1996-03-12 | Cephalon, Inc. | Cysteine protease and serine protease inhibitors |
| US5804560A (en) * | 1995-01-06 | 1998-09-08 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
| US5872101A (en) * | 1995-01-06 | 1999-02-16 | Sibia Neurosciences, Inc. | Methods of treating neurodegenerative disorders using protease inhibitors |
| US5776718A (en) * | 1995-03-24 | 1998-07-07 | Arris Pharmaceutical Corporation | Reversible protease inhibitors |
| US6162828A (en) * | 1995-03-31 | 2000-12-19 | Takeda Chemical Industries, Ltd. | Cysteine protease inhibitor |
| JP2000500742A (ja) | 1995-10-30 | 2000-01-25 | スミスクライン・ビーチャム・コーポレイション | プロテアーゼ阻害剤 |
| US6586466B2 (en) | 1995-10-30 | 2003-07-01 | Smithkline Beecham Corporation | Carbohydrazide-protease inhibitors |
| US5843904A (en) * | 1995-12-20 | 1998-12-01 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1βconverting enzyme |
| DZ2285A1 (fr) * | 1996-08-08 | 2002-12-25 | Smithkline Beecham Corp | Inhibiteurs de protéase de la cystéine. |
| US5830850A (en) * | 1996-08-28 | 1998-11-03 | Mount Sinai School Of Medicine Of The City Of New York | Methods for the treatment of bone resorption disorders, including osteoporosis |
| ES2205760T3 (es) * | 1998-04-30 | 2004-05-01 | Agouron Pharmaceuticals, Inc. | Compuestos antipicornavirales, su preparacion y su utilizacion. |
| CO5150165A1 (es) * | 1998-11-13 | 2002-04-29 | Smithkline Beecham Plc | Inhibidores de proteasa: tipo catepsina k |
| US6143079A (en) * | 1998-11-19 | 2000-11-07 | Asm America, Inc. | Compact process chamber for improved process uniformity |
| US20030144175A1 (en) | 1998-12-23 | 2003-07-31 | Smithkline Beecham Corporation | Protease inhibitors |
| UY26026A1 (es) * | 1999-03-16 | 2000-10-31 | Smithkline Beecham Corportion | Inhibidores de proteasas |
| UY26088A1 (es) * | 1999-03-31 | 2000-10-31 | Smithkline Beecham Corp | Inhibidores de proteasas |
| WO2001010894A2 (en) | 1999-08-04 | 2001-02-15 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
| JP2003513971A (ja) | 1999-11-10 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | プロテア−ゼ阻害剤 |
| US6583137B1 (en) | 1999-11-10 | 2003-06-24 | Smithkline Beecham Corporation | Protease inhibitors |
| JP2003513924A (ja) | 1999-11-10 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | プロテア−ゼ阻害剤 |
| PE20020157A1 (es) | 1999-12-03 | 2002-02-22 | Agouron Pharma | Compuestos derivados de piridona como inhibidores de proteasas de picornaviral 3c, composiciones, sus usos farmaceuticos y materiales para su sintesis |
| IL150964A0 (en) | 2000-03-21 | 2003-02-12 | Smithkline Beecham Corp | Protease inhibitors |
| PA8515201A1 (es) * | 2000-04-14 | 2002-10-24 | Agouron Pharma | Compuestos y composiciones antipicornavirales; sus usos farmaceuticos y los materiales para su sintesis |
| MXPA02012456A (es) | 2000-06-14 | 2004-01-26 | Agouron Pharma | Compuestos y composiciones antipicornavirales, sus usos farmaceuticos y materiales para su sintesis. |
| US7109243B2 (en) * | 2003-03-24 | 2006-09-19 | Irm Llc | Inhibitors of cathepsin S |
| US7384970B2 (en) * | 2003-03-24 | 2008-06-10 | Irm Llc | Inhibitors of cathepsin S |
| US7173051B2 (en) * | 2003-06-13 | 2007-02-06 | Irm, Llc | Inhibitors of cathepsin S |
| US7256207B2 (en) * | 2003-08-20 | 2007-08-14 | Irm Llc | Inhibitors of cathepsin S |
| EP1701728A2 (de) * | 2003-12-30 | 2006-09-20 | Aventis Pharmaceuticals, Inc. | Verwendung von cathepsin-z-hemmern zur behandlung von rheumatoider arthritis und anderer autoimmunkrankheiten |
| KR20080021634A (ko) | 2005-06-02 | 2008-03-07 | 쉐링 코포레이션 | 약제학적 조성물 및 이를 사용한 치료 방법 |
| NZ563361A (en) | 2005-06-02 | 2011-02-25 | Schering Corp | HCV protease inhibitors in combination with food |
| JP5587790B2 (ja) | 2008-01-09 | 2014-09-10 | アミュラ セラピューティクス リミティド | 化合物 |
| GB0804701D0 (en) | 2008-03-13 | 2008-04-16 | Amura Therapeutics Ltd | Compounds |
| EP2198879A1 (de) | 2008-12-11 | 2010-06-23 | Institut Curie | CD74-modulierender Wirkstoff zur Regulierung der Dendritenzellmigration und Verfahren zur Untersuchung der Bewegungsfähigkeit einer Zelle |
| JP6642948B2 (ja) | 2014-10-06 | 2020-02-12 | コーテクシーミー， インコーポレイテッド | リシンジンジパインの阻害剤 |
| WO2017083433A1 (en) | 2015-11-09 | 2017-05-18 | Cortexyme, Inc. | Inhibitors of arginine gingipain |
| DK3512846T3 (da) | 2016-09-16 | 2024-11-11 | Lighthouse Pharmaceuticals Inc | Ketonhæmmere af lysin-gingipain |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518528A (en) * | 1983-05-19 | 1985-05-21 | Rasnick David W | α Amino fluoro ketones |
| US5055451A (en) * | 1986-12-22 | 1991-10-08 | Syntex Inc. | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors |
| GB9019558D0 (en) * | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
-
1992
- 1992-08-20 US US07/932,791 patent/US5374623A/en not_active Expired - Fee Related
-
1993
- 1993-08-18 AT AT93920167T patent/ATE180772T1/de not_active IP Right Cessation
- 1993-08-18 DE DE69325178T patent/DE69325178T2/de not_active Expired - Fee Related
- 1993-08-18 JP JP6506506A patent/JPH08502245A/ja not_active Ceased
- 1993-08-18 EP EP93920167A patent/EP0667854B1/de not_active Expired - Lifetime
- 1993-08-18 WO PCT/US1993/007767 patent/WO1994004172A1/en active IP Right Grant
- 1993-08-18 AU AU50190/93A patent/AU5019093A/en not_active Abandoned
- 1993-08-18 CA CA002142839A patent/CA2142839A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JPH08502245A (ja) | 1996-03-12 |
| AU5019093A (en) | 1994-03-15 |
| EP0667854B1 (de) | 1999-06-02 |
| CA2142839A1 (en) | 1994-03-03 |
| EP0667854A4 (de) | 1995-07-04 |
| US5374623A (en) | 1994-12-20 |
| DE69325178D1 (de) | 1999-07-08 |
| DE69325178T2 (de) | 2000-02-03 |
| WO1994004172A1 (en) | 1994-03-03 |
| EP0667854A1 (de) | 1995-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE180772T1 (de) | Durch peptidylketon aktivierte inhibitoren, die natürliche und nicht-natürliche peptidsequenzen enthalten | |
| Llorens et al. | Rational design of enkephalinase inhibitors: substrate specificity of enkephalinase studied from inhibitory potency of various dipeptides | |
| Lauer et al. | Sequence dependence of aspartimide formation during 9-fluorenylmethoxycarbonyl solid-phase peptide synthesis | |
| CA1160973A (en) | Process for enzymatic production of peptides | |
| TW377350B (en) | Peptidic ketones as interleukin-1beta-converting enzyme inhibitors | |
| Fukase et al. | Total synthesis of peptide antibiotic nisin | |
| DK0910571T3 (da) | Hidtil ukendte antiangiogene peptider, polynucleotider, der koder for samme, samt fremgangsmåder til inhibering af angiogenese | |
| de Bont et al. | Increased stability of peptidesulfonamide peptidomimetics towards protease catalyzed degradation | |
| ES2063350T3 (es) | Nuevas proteinas con efecto inhibidor del tnf y su produccion. | |
| WO2003089457B1 (en) | Peptide inhibitors of protein kinase c ϝ for pain management | |
| KR890000514A (ko) | 트립신형 프로테아제의 펩타이드 붕산 억제제 | |
| GR3031169T3 (en) | Cd8 binding domain peptides. | |
| DK0479912T3 (da) | Fremgangsmåde til hæmning af N-endereglens forløb i levende celler | |
| EP0640687A1 (de) | Verfahren zur Anwendung, Lagern und Transport des Proteaseenzymes im stabilisierter Form | |
| Gettins et al. | Identification of proton resonances from the bait region of human. alpha. 2-macroglobulin and effects of proteases and methylamine | |
| Lee et al. | Cathepsin B inhibitory peptides derived from β-casein | |
| FI956055A0 (fi) | Tekijä VII:sta johdettuja peptidejä | |
| ES488382A1 (es) | Procedimiento para la preparacion de lh-rh o de analogos de lh-rh | |
| KR910007960A (ko) | 항응고성 펩티드 | |
| EP0124420A3 (en) | Gastric secretion inhibiting peptide derivatives, process for their preparation and medicines containing them | |
| Crumpton et al. | The C-terminal antigenic site of sperm-whale myoglobin: the immunological activities of synthetic peptides related to the C-terminus of myoglobin | |
| ATE82984T1 (de) | Hemmende peptide. | |
| Križaj et al. | The complete primary structure of bovine stefin B | |
| ATE25984T1 (de) | Pharmakologisch aktive peptide. | |
| Yaron | The use of synthetic polyamino acids for the detection and purification of novel proteolytic enzymes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |